Stelliam Investment Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Stelliam Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,702,500	Closed	-$91.1M	–	48
2016 Q1	$91.1M	Buy	1,702,500 +437,500	+35%	+$25.7M	2.82%	15
2015 Q4	$83M	Sell	1,265,000 -380,000	-23%	-$23.5M	2.48%	16
2015 Q3	$92.9M	Buy	1,645,000 +285,000	+21%	+$18.5M	2.31%	14
2015 Q2	$80.4M	Buy	1,360,000 +270,000	+25%	+$16.7M	1.7%	21
2015 Q1	$67.9M	Sell	1,090,000 -165,000	-13%	-$9.59M	1.53%	28
2014 Q4	$72.2M	Buy	1,255,000 +337,500	+37%	+$18.8M	1.66%	21
2014 Q3	$49.3M	Buy	+917,500	New	+$48.6M	1.3%	40
2013 Q4	–	Sell	-1,837,500	Closed	-$69.4M	–	57
2013 Q3	$69.4M	Buy	1,837,500 +455,000	+33%	+$17.7M	3.31%	4
2013 Q2	$54.2M	Buy	+1,382,500	New	+$53.8M	2.94%	9

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Stelliam Investment Management's TEVA Position: Q2 2016 in Review

Stelliam Investment Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2016, closing a stake of 1,702,500 shares — an estimated $91.1M sold.

Stelliam Investment Management first reported a position in TEVA in Q2 2013 and held it in 9 quarters. The position peaked at $92.9M in Q3 2015. 813 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

Stelliam Investment Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2016 after selling out during the quarter.
Stelliam Investment Management sold 1,702,500 Teva Pharmaceutical Industries Limited shares in Q2 2016, an estimated $91.1M.
Stelliam Investment Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and held it in 9 quarters.
Stelliam Investment Management's Teva Pharmaceutical Industries Limited position peaked at $92.9M in Q3 2015.
813 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2016.

Based on Stelliam Investment Management's 13F filing for Q2 2016, filed 15 Aug 2016.